8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 3, 2026·SEC
TransCode Therapeutics, Inc.(RNAZ)Earnings, Financials & Key Ratios
RNAZ•NASDAQ
Price updated Jun 19, 2026
AboutTransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$28M-84.2%
- Net Income-$35M-106.9%
- EPS (Diluted)-52.59-11.6%
- ROE-833.53%
RNAZ Key Insights
TransCode Therapeutics, Inc. (RNAZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 71.4% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 93.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RNAZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNAZ Price & Volume
TransCode Therapeutics, Inc. (RNAZ) stock price & volume — 10-year historical chart
Loading chart...
RNAZ Growth Metrics
TransCode Therapeutics, Inc. (RNAZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.31%
Return on Capital
10 Years-310.76%
5 Years-309%
3 Years-442.89%
Last Year-34.24%
RNAZ Recent Earnings
TransCode Therapeutics, Inc. (RNAZ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (55%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$21.28
—
Rev
—
—
Q2 2026
Apr 15, 2026Metric
Actual
Est
EPS
$16.42-62.9%
$10.08
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$5.49+40.6%
$9.24
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$4.94+43.1%
$8.68
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $21.28 | — |
| Q2 2026 | Apr 15, 2026 | $16.42vs $10.08-62.9% | — |
| Q4 2025 | Nov 14, 2025 | $5.49vs $9.24+40.6% | — |
| Q3 2025 | Aug 14, 2025 | $4.94vs $8.68+43.1% | — |
Based on last 12 quarters of dataView full earnings history →
RNAZ Peer Comparison
TransCode Therapeutics, Inc. (RNAZ) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 STRO | 286.74M | 29.63 | -1.32 | 65.18% | -154.21% | |||
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare RNAZ vs Peers
TransCode Therapeutics, Inc. (RNAZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNAZ Income Statement
TransCode Therapeutics, Inc. (RNAZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 0 | 28.72K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -42.47K▲ 0% | -98.61K▼ 132.2% | -516.75K▼ 424.1% | -534.86K▼ 3.5% | 0▲ 100.0% | -28.72K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | -132.18% | -424.05% | -3.5% | 100% | - |
Operating Expenses | 384.52K | 456.87K | 726.6K | 6.11M | 18.57M | 18.9M | 15.13M | 27.98M | 32.11M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 301.46K | 230.56K | 442.14K | 3.35M | 8.33M | 6.64M | 5.51M | 5.77M | 2.23B |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 82.53K | 226.31K | 284.46K | 2.75M | 10.23M | 12.26M | 9.62M | 13.42M | 5.12B |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.79M | 0 |
Operating Income | -384K▲ 0% | -456.87K▼ 19.0% | -726.6K▼ 59.0% | -6.15M▼ 746.6% | -18.67M▼ 203.5% | -19.42M▼ 4.0% | -15.66M▲ 19.4% | -27.98M▼ 78.7% | -32.14M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -18.98% | -59.04% | -746.56% | -203.45% | -4.03% | 19.35% | -78.66% | - |
EBITDA | 0 | -450.25K | -1.95M | -6.11M | -18.57M | -18.9M | -15.13M | -27.87M | -32.05M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -332.94% | -213.37% | -203.95% | -1.8% | 19.98% | -84.23% | -112.28% |
D&A (Non-Cash Add-back) | 384K | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 114.18K | 86.94K |
EBIT | -384K | -450.25K | -1.95M | -6.75M | -17.56M | -18.49M | -16.73M | -34.43M | -29.67M |
Net Interest Income | 0 | -156.93K | -394.44K | -94.41K | -17.54M | -50.61K | -26.13K | 72.58K | 164.44K |
Interest Income | 68.92K | 34 | 136 | 664 | 20.41K | 5.29K | 684 | 79.2K | 170.94K |
Interest Expense | 0 | 156.97K | 394.57K | 95.07K | 17.56M | 55.9K | 26.81K | 6.62K | 6.5K |
Other Income/Expense | -69.44K | -150.35K | -1.62M | -692.26K | 1.1M | 872.42K | -1.09M | -6.45M | -7.77M |
Pretax Income | -453.44K▲ 0% | -607.21K▼ 33.9% | -2.34M▼ 286.0% | -6.84M▼ 192.0% | -17.56M▼ 156.7% | -18.55M▼ 5.6% | -16.75M▲ 9.7% | -34.44M▼ 105.5% | -39.9M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 226.07K | 457.38K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.66% | -1.15% |
Net Income | -453.44K▲ 0% | -607.21K▼ 33.9% | -2.34M▼ 286.0% | -6.84M▼ 192.0% | -17.56M▼ 156.7% | -18.55M▼ 5.6% | -16.75M▲ 9.7% | -34.66M▼ 106.9% | -40.36M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -33.91% | -286.01% | -191.97% | -156.67% | -5.59% | 9.66% | -106.87% | -58.19% |
Net Income (Continuing) | -453.44K | -607.21K | -2.34M | -6.84M | -17.56M | -18.55M | -16.75M | -34.66M | -40.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2359.09▲ 0% | -72.00▲ 96.9% | -293.76▼ 308.0% | -648.00▼ 120.6% | -1080.00▼ 66.7% | -3453.53▼ 219.8% | -47.14▲ 98.6% | -52.59▼ 11.6% | -44.02▲ 0% |
EPS Growth % | - | 96.95% | -308% | -120.59% | -66.67% | -219.77% | 98.63% | -11.56% | 49.31% |
EPS (Basic) | -2359.09 | -72.00 | -293.76 | -648.00 | -73187.37 | -3453.65 | -47.14 | -52.59 | - |
Diluted Shares Outstanding | 192 | 6.41K | 7.98K | 10.53K | 16.22K | 5.42K | 356.12K | 689.71K | 916.97K |
Basic Shares Outstanding | 192 | 6.41K | 7.98K | 10.53K | 16.22K | 5.42K | 356.12K | 689.71K | 916.97K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RNAZ Balance Sheet
TransCode Therapeutics, Inc. (RNAZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 214.65K | 204.47K | 831.22K | 22.73M | 7.38M | 4.46M | 7.09M | 21.98M | 16.75M |
Cash & Short-Term Investments | 212.98K | 204.47K | 828.02K | 20.83M | 4.98M | 2.77M | 5.81M | 17.81M | 12.84M |
Cash Only | 212.98K | 204.47K | 828.02K | 20.83M | 4.97M | 2.77M | 5.81M | 17.81M | 12.84M |
Short-Term Investments | 0 | 0 | 0 | 0 | 9.41K | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.25M | 2.3M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 1.84M | 1.02M | 1.14M | 517.48K | 529.04K | 1.02M |
Total Non-Current Assets | 0 | 12.27K | 224.15K | 206.27K | 208.58K | 714.26K | 201.16K | 140.41M | 140.42M |
Property, Plant & Equipment | 0 | 0 | 0 | 206.27K | 208.58K | 602.4K | 89.31K | 370.68K | 346.75K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.74M | 25.74M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 114.3M | 114.3M |
Long-Term Investments | 0 | 12.27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 224.15K | 0 | 0 | 111.86K | 111.86K | 0 | 25K |
Total Assets | 214.65K▲ 0% | 216.74K▲ 1.0% | 1.06M▲ 386.9% | 22.94M▲ 2073.5% | 7.59M▼ 66.9% | 5.17M▼ 31.9% | 7.29M▲ 41.1% | 162.4M▲ 2126.3% | 157.16M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 0.98% | 386.92% | 2073.5% | -66.92% | -31.87% | 41.1% | 2126.32% | 3321.63% |
Total Current Liabilities | 117.68K | 62.94K | 404.86K | 2.53M | 4.35M | 3.49M | 2.77M | 3.49M | 5.38M |
Accounts Payable | 0 | 27.26K | 0 | 2.02M | 0 | 0 | 2.58M | 0 | 5M |
Days Payables Outstanding | - | - | - | 17.33K | - | - | 1.76K | - | 20.21K |
Short-Term Debt | 35.69K | 0 | 0 | 0 | 0 | 0 | 38.29K | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 30.53K | 0 | 27.06K | 0 | 0 | 0 |
Other Current Liabilities | 0 | 35.69K | -1 | -2.02M | 0 | 0 | 26.11K | 0 | 128.5K |
Current Ratio | 1.82x | 3.25x | 2.05x | 8.97x | 1.70x | 1.28x | 2.56x | 6.29x | 3.11x |
Quick Ratio | 1.82x | 3.25x | 2.05x | 8.97x | 1.70x | 1.28x | 2.56x | 6.29x | 3.11x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 600.93K | 1.25M | 4.06M | 0 | 0 | 38.29K | 6.54M | 148.57M | 7.27M |
Long-Term Debt | 436.21K | 927.81K | 2.09M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 38.29K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 226.07K | 683.45K |
Other Non-Current Liabilities | 164.72K | 323.5K | 1.97M | 0 | 0 | 0 | 6.54M | 148.34M | 6.81M |
Total Liabilities | 718.61K | 1.31M | 4.46M | 2.53M | 4.35M | 3.53M | 9.31M | 152.06M | 12.64M |
Total Debt | 471.9K | 927.81K | 2.09M | 0 | 0 | 450.57K | 38.29K | 0 | 0 |
Net Debt | 258.92K | 723.34K | 1.26M | -20.83M | -4.97M | -2.32M | -5.77M | -17.81M | -12.84M |
Debt / Equity | - | - | - | - | - | 0.27x | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.40x |
Interest Coverage | - | -2.87x | -4.94x | -70.98x | -1.00x | -330.78x | -623.88x | -5203.81x | -4563.50x |
Total Equity | -503.97K▲ 0% | -1.1M▼ 117.8% | -3.41M▼ 210.5% | 20.4M▲ 698.7% | 3.24M▼ 84.1% | 1.64M▼ 49.4% | -2.02M▼ 223.0% | 10.34M▲ 612.0% | 144.52M▲ 0% |
Equity Growth % | - | -117.77% | -210.54% | 698.68% | -84.12% | -49.37% | -223.03% | 611.98% | 2267.29% |
Book Value per Share | -2621.96 | -171.30 | -427.15 | 1937.37 | 199.78 | 302.49 | -5.67 | 14.99 | 157.61 |
Total Shareholders' Equity | -503.97K | -1.1M | -3.41M | 20.4M | 3.24M | 1.64M | -2.02M | 10.34M | 144.52M |
Common Stock | 764 | 764 | 464 | 1.29K | 2 | 63 | 103 | 92 | 92 |
Retained Earnings | -510.78K | -1.12M | -3.46M | -10.31M | -27.87M | -46.42M | -63.2M | -97.86M | -115.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -11.8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAZ Cash Flow Statement
TransCode Therapeutics, Inc. (RNAZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -299.57K | -508.51K | -492.97K | -5.27M | -15.76M | -18.07M | -13.34M | -19.52M | -4.99B |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -69.74% | 3.06% | -968.4% | -199.28% | -14.67% | 26.22% | -46.34% | -160880.76% |
Net Income | -453.44K | -607.21K | -2.34M | -6.84M | -17.56M | -18.55M | -16.75M | -34.66M | -40.36M |
Depreciation & Amortization | 0 | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 114.18K | 17.61M |
Stock-Based Compensation | 22.38K | 1.4K | 45.44K | 186K | 395.33K | 1.04M | 1.7M | 485.43K | -95.71M |
Deferred Taxes | 0 | 0 | 0 | 876.19K | 0 | 0 | 0 | 0 | 457.38M |
Other Non-Cash Items | 106.55K | 102.01K | 1.5M | 39.47K | 0 | 0 | 1.54M | 14.53M | 13.79B |
Working Capital Changes | 24.94K | -4.7K | 309.76K | 432.39K | 1.31M | -1.08M | -351.48K | 15.57K | 2.59M |
Change in Receivables | 0 | 0 | 0 | 0 | -360.23K | 360.23K | 0 | -952.46K | 322.44K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | -54.74K | 191.25K | 2.29M | 1.84M | 0 | 0 | 0 | 2.19M |
Cash from Investing | 0 | 0 | 0 | -251.82K | -100.92K | -35.61K | -21.76K | -4.44K | -4.44K |
Capital Expenditures | 0 | 0 | 0 | -254.82K | -100.92K | -35.61K | -21.76K | -6.66K | -6.66K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 2.22K | 2.22K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 512.43K | 500K | 1.12M | 25.52M | 5.99K | 15.91M | 16.4M | 31.52M | 22.67M |
Debt Issued (Net) | 550K | 500K | 1.19M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 26.34M | 5.99K | 15.91M | 16.4M | 31.52M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.73B |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -37.57K | 0 | -73.48K | -818.55K | 0 | 0 | 0 | 0 | 1.75B |
Net Change in Cash | 212.86K▲ 0% | -8.51K▼ 104.0% | 623.54K▲ 7428.9% | 20M▲ 3107.1% | -15.86M▼ 179.3% | -2.2M▲ 86.1% | 3.04M▲ 238.3% | 12M▲ 294.4% | -4.97B▲ 0% |
Free Cash Flow | -299.57K▲ 0% | -508.51K▼ 69.7% | -492.97K▲ 3.1% | -5.52M▼ 1020.1% | -15.86M▼ 187.3% | -18.11M▼ 14.2% | -13.36M▲ 26.2% | -19.52M▼ 46.2% | -4.99B▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -69.74% | 3.06% | -1020.09% | -187.29% | -14.16% | 26.24% | -46.15% | -39812.38% |
FCF per Share | -1558.57 | -79.37 | -61.78 | -524.28 | -977.96 | -3338.63 | -37.51 | -28.31 | -5446.75 |
FCF Conversion (FCF/Net Income) | 0.66x | 0.84x | 0.21x | 0.77x | 0.90x | 0.97x | 0.80x | 0.56x | 123.75x |
Interest Paid | 0 | 0 | 0 | 17.87K | 0 | 32.86K | 16.63K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAZ Key Ratios
TransCode Therapeutics, Inc. (RNAZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -80.53% | -148.57% | -759.85% | - | -833.53% | -99.39% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -79.31% |
Debt / Equity | - | - | - | - | 0.27x | - | - | 0.00x |
Interest Coverage | -2.87x | -4.94x | -70.98x | -1.00x | -330.78x | -623.88x | -5203.81x | -4563.50x |
FCF Conversion | 0.84x | 0.21x | 0.77x | 0.90x | 0.97x | 0.80x | 0.56x | 123.75x |
Related:RNAZ Dividend History·RNAZ Revenue History·RNAZ Price History·RNAZ P/E History·RNAZ Financial Ratios·RNAZ Institutional Holders
RNAZ SEC Filings & Documents
TransCode Therapeutics, Inc. (RNAZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
RNAZ Frequently Asked Questions
TransCode Therapeutics, Inc. (RNAZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TransCode Therapeutics, Inc. (RNAZ) grew revenue by 0.0% over the past year. Growth has been modest.
TransCode Therapeutics, Inc. (RNAZ) reported a net loss of $40.4M for fiscal year 2025.
Dividend & Returns
TransCode Therapeutics, Inc. (RNAZ) has a return on equity (ROE) of -833.5%. Negative ROE indicates the company is unprofitable.
TransCode Therapeutics, Inc. (RNAZ) had negative free cash flow of $4.99B in fiscal year 2025, likely due to heavy capital investments.